The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

BACKGROUND: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte inf...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Epigenetics
Prif Awduron: Zhao, Hongjuan, Ning, Shoucheng, Nolley, Rosalie, Scicinski, Jan, Oronsky, Bryan, Knox, Susan J., Peehl, Donna M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5270305/
https://ncbi.nlm.nih.gov/pubmed/28149332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-017-0312-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg